100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Feb. 02, 2016 -- Ocera Therapeutics, Inc. (NASDAQ:OCRX), a clinical stage biopharmaceutical company focused on acute and chronic orphan liver diseases, today announced that the Company will be presenting at the 18th Annual BIO CEO & Investor Conference taking place February 8 - 9, 2016 at the Waldorf Astoria in New York, NY. Ocera’s management will present at 10:00 AM ET on Tuesday, February 9th, in the Conrad room in the conference’s Orphan/Rare Diseases track.
A live audio webcast of the presentation will be available in the "Investors" section of Ocera's website, www.ocerainc.com. A replay of the presentation will be available for 90 days following the conference for those unable to listen live.
About Ocera
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous and oral formulations. OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease. For additional information, please see www.ocerainc.com.
Susan Sharpe Ocera Therapeutics, Inc. [email protected] 919-328-1109
